Treatment of adoptively transferred TCL1 leukemias with R788. (A) Analysis of mice with adoptively transferred TCL1-002, TCL1-551, or TCL1-870 leukemia after treatment with R788 or vehicle control. B6/C3H F1 female mice (6-8 weeks old) received 1.5 × 10⁷ leukemia cells by intraperitoneal injection. Three days later treatment was initiated with R788 (80 mg/kg/d) or vehicle control (Cont.). Mice with TCL1-002 leukemia were treated for 18 days, whereas mice with TCL1-551 and TCL1-870 leukemia were treated for 21 days. Peripheral blood samples were collected on the indicated days, and the percentage of malignant CD5⁺/B220⁺ cells was determined by flow cytometry. (B) Kaplan-Meier survival curves of mice with adoptively transferred TCL1-002 and TCL1-551 leukemia treated with R788 or vehicle control. The period of treatment (Rx) is indicated by arrows. (C) Complete blood counts in mice with adoptively transferred TCL1-002 leukemia on the last day of treatment. Analysis was performed on a HEMAVET 950 counter. Values represent mean absolute cell counts ± SD × 10⁶/mL for WBCs, Ne, Mo, Ly, and B and T cells, × 10⁹/mL for RBCs, and × 10⁸/mL for Pts (control group n = 10, R788 group n = 8). The absolute number of normal B and T cells was calculated using the percentage of CD5^-/B220⁺ and CD5⁺/B220⁻ cells from the flow cytometric analysis.